Department of Electrical and Computer Engineering, Division of Systems Engineering, Boston University, 8 Saint Mary's St., Boston, MA, 02215, USA.
Department of Medicine, Boston Medical Center, School of Medicine, Boston University, Boston, MA, USA.
BMC Med Inform Decis Mak. 2023 Mar 1;23(1):44. doi: 10.1186/s12911-023-02137-z.
Hypertension is a prevalent cardiovascular disease with severe longer-term implications. Conventional management based on clinical guidelines does not facilitate personalized treatment that accounts for a richer set of patient characteristics.
Records from 1/1/2012 to 1/1/2020 at the Boston Medical Center were used, selecting patients with either a hypertension diagnosis or meeting diagnostic criteria (≥ 130 mmHg systolic or ≥ 90 mmHg diastolic, n = 42,752). Models were developed to recommend a class of antihypertensive medications for each patient based on their characteristics. Regression immunized against outliers was combined with a nearest neighbor approach to associate with each patient an affinity group of other patients. This group was then used to make predictions of future Systolic Blood Pressure (SBP) under each prescription type. For each patient, we leveraged these predictions to select the class of medication that minimized their future predicted SBP.
The proposed model, built with a distributionally robust learning procedure, leads to a reduction of 14.28 mmHg in SBP, on average. This reduction is 70.30% larger than the reduction achieved by the standard-of-care and 7.08% better than the corresponding reduction achieved by the 2nd best model which uses ordinary least squares regression. All derived models outperform following the previous prescription or the current ground truth prescription in the record. We randomly sampled and manually reviewed 350 patient records; 87.71% of these model-generated prescription recommendations passed a sanity check by clinicians.
Our data-driven approach for personalized hypertension treatment yielded significant improvement compared to the standard-of-care. The model implied potential benefits of computationally deprescribing and can support situations with clinical equipoise.
高血压是一种常见的心血管疾病,具有严重的长期影响。基于临床指南的常规管理并不能促进针对更丰富的患者特征的个性化治疗。
使用了 2012 年 1 月 1 日至 2020 年 1 月 1 日在波士顿医疗中心的记录,选择了有高血压诊断或符合诊断标准(收缩压≥130mmHg 或舒张压≥90mmHg,n=42752)的患者。为每个患者开发了基于其特征推荐抗高血压药物类别的模型。回归免疫处理异常值,并结合最近邻方法,将每个患者与其他患者的亲和组相关联。然后,使用该组对每种处方类型下的未来收缩压(SBP)进行预测。对于每个患者,我们利用这些预测来选择可将其未来预测 SBP 最小化的药物类别。
所提出的模型,使用分布鲁棒学习程序构建,平均可使 SBP 降低 14.28mmHg。与标准治疗相比,这一降低幅度高出 70.30%,比使用普通最小二乘回归的第二佳模型的相应降低幅度高出 7.08%。所有推导的模型在记录中都优于遵循先前处方或当前真实处方的情况。我们随机抽样并手动审查了 350 份患者记录;其中 87.71%的模型生成的处方建议通过了临床医生的合理性检查。
与标准治疗相比,我们针对个性化高血压治疗的基于数据的方法取得了显著的改善。该模型暗示了计算性减药的潜在好处,并可以支持临床平衡的情况。